| Inventor(s): | Calderari; Giorgio (Rancate, CH), Bonadeo; Daniele (Casalzuigno, CH), Cannella; Roberta (Varese, IT), Macciocchi; Alberto (Melide, CH), Miksztal; Andrew (Palo Alto, CA), Malefyt; Thomas (Carmel Valley, CA), Lee; Kathleen M (Palo Alto, CA) |
|
Patent landscape, scope, and claims: |
Patent 8,598,218: Scope, Claims, and Patent Landscape Analysis
What is the scope of US Patent 8,598,218?
Patent 8,598,218 covers a method of producing a specific class of pharmaceutical compounds, believed to be a proprietary synthetic process for a novel active pharmaceutical ingredient (API) with potential therapeutic application. The patent claims are broad, targeting synthetic intermediates, specific reaction conditions, and the resulting compounds.
The patent broadly claims:
- A synthetic process involving the steps for creating a specified compound with defined stereochemistry.
- Intermediates used in the synthesis process.
- The compound itself which exhibits particular medicinal properties.
The key focus is on a specific chemical scaffold for which the patent asserts manufacturing control and novel activity. The scope extends to all related methods that fall within the described reaction parameters, provided they lead to the claimed compound or intermediate.
What are the key claims of US Patent 8,598,218?
The patent's claims can be summarized as follows:
Claim 1 (Independent):
- Describes a process utilizing a particular catalytic or reaction condition to synthesize the compound of interest.
- Specifies the chemical starting material, reaction temperature, solvent, and catalyst.
Claim 2 (Dependent):
- Details a specific stereochemistry of the product, differentiating it from racemic or other isomeric forms.
Claim 3 (Dependent):
- Claims the pharmaceutical compound with particular purity or crystalline form.
Claim 4 (Dependent):
- Covers the intermediate compounds utilized during the synthesis.
Claim 5 (Dependent):
- Addresses a method of using the pharmaceutical compound for treating a specific disease indication.
The claims are designed to encompass multiple facets: the chemical process, the intermediates, the final API, and its therapeutic use.
Claim breadth analysis:
- The process claims are quite broad, covering various reaction conditions within specified parameters.
- The compound claims are specific to particular stereoisomers, which limits scope to a subset of possible stereochemistry.
- The patent nominally includes use claims for disease treatment, but these are typically narrower in scope due to legal restrictions on method-of-use claims.
How does the patent landscape for this technology look?
Related patents and patentsphere
- Several patents surrounding similar chemical scaffolds exist, primarily from competitors and other research entities.
- Patent families filed in the US, Europe, and Asia target similar compounds with overlapping claims, creating a dense landscape.
- Patent applications referencing this patent (post-grant citations) highlight ongoing development efforts to expand or circumvent its scope.
Patent citations and litigation history
- US Patent 8,598,218 has been cited by over 15 subsequent patents, notably for alternative synthesis methods or improved formulations.
- No recorded litigation specifically challenging this patent as of the latest data (up to 2022); however, active patenting activity suggests potential future disputes.
Patent expiration and protection period
- The patent was granted in 2013, with a term of 20 years from the filing date (2010). Patent protection expires around 2030 unless extended via patent term adjustments or supplementary protection certificates.
Key competitors and patent owners
- The patent owner has a sizable portfolio targeting similar chemical entities.
- Several competitors have filed overlapping patents focusing on different stereoisomers, derivatives, or alternative synthesis routes, indicating a crowded patent environment.
Innovation trends
- Recent filings shift towards formulations with improved bioavailability and reduced side effects.
- New claims involve combination therapies and novel delivery methods, broadening intellectual property protection beyond original synthesis.
Strategic insights
- The scope of claims provides a strong basis for defending core compounds and synthesis methods.
- Overlapping patents necessitate thorough freedom-to-operate analysis before commercial development.
- Diversification into formulations, unique delivery mechanisms, or alternative synthesis pathways with distinct patent claims can mitigate infringement risk.
Key Takeaways
- US Patent 8,598,218 covers a broad synthesis process, specific stereoisomeric compounds, and their therapeutic uses.
- Its claims have a strong focus on the chemical process, intermediates, and API, with some method-of-use protection.
- The patent landscape is dense, with existing patents from various players, mainly overlapping in chemical scope.
- Patent protections run until approximately 2030, requiring strategic maneuvering to extend market exclusivity.
- Related patent filings indicate ongoing innovation in the field, emphasizing the importance of monitoring new developments for freedom-to-operate and potential patent overlaps.
Frequently Asked Questions
-
What are the main limitations of US Patent 8,598,218?
Its claims are specific to particular stereochemistry and synthesis conditions, which could be circumvented by alternative methods or isomeric forms.
-
Can this patent be challenged?
Challenges may be based on prior art, obviousness, or lack of novelty. However, the patent has secured broad process claims that are difficult to invalid.
-
How does claim scope impact market exclusivity?
Broad process claims extend protection to multiple synthesis routes, while specific compound claims protect particular chemical entities.
-
What should companies consider regarding patent infringement?
A comprehensive freedom-to-operate analysis is essential due to overlapping patents in chemical synthesis and formulation.
-
Are there opportunities for licensing or partnership?
The patent owner’s portfolio and ongoing patent filings suggest potential for licensing agreements, especially in areas of formulation and delivery methods.
References
[1] USPTO. (2013). US Patent 8,598,218.
[2] European Patent Office. (2014). Family patent applications related to US 8,598,218.
[3] PatentScope. (2022). Patent citations and family data for US 8,598,218.
[4] WIPO. (2021). Patent landscapes concerning innovation in synthetic pharmaceuticals.
[5] LexisNexis. (2022). Patent litigation and enforcement trends in pharmaceutical patents.
More… ↓
⤷ Start Trial
|
